Integrins mediate cell adhesion and transmit mechanical and chemical signals to the cell
interior. Various mechanisms deregulate integrin signaling in cancer, empowering tumor …

Integrins are vital surface adhesion receptors that mediate interactions between the
extracellular matrix (ECM) and cells and are essential for cell migration and the …

Therapeutic targeting of Bruton tyrosine kinase (BTK) has dramatically improved survival
outcomes for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma …

Spleen tyrosine kinase (SYK) is known to have a crucial role in adaptive immune receptor
signalling. However, recent reports indicate that SYK also mediates other, unexpectedly …

Small-molecule drugs that target the B-cell antigen receptor (BCR) signalosome show
clinical efficacy in the treatment of B-cell non-Hodgkin lymphoma. These agents, including …

Targeted therapy with imatinib and other selective tyrosine kinase inhibitors has transformed
the treatment of chronic myeloid leukemia. Unlike chronic myeloid leukemia, chronic …

Retinoblastoma is an aggressive childhood cancer of the developing retina that is initiated
by the biallelic loss of RB1. Tumours progress very quickly following RB1 inactivation but the …

The B-cell receptor (BCR) is a key survival molecule for normal B cells and for most B-cell
malignancies. Recombinatorial and mutational patterns in the clonal immunoglobulin (Ig) of …

B-cell antigen receptor (BCR) expression is an important feature of chronic lymphocytic
leukaemia (CLL), one of the most prevalent B-cell neoplasias in Western countries. The …

The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has outstanding activity in patients with
chronic lymphocytic leukemia. Most patients experience lymphocytosis, representing …